In a woman aged 20‑40 years presenting with fatigue, jaundice, right‑upper‑quadrant discomfort, transaminases >10 × upper limit of normal, hypergammaglobulinemia and positive antinuclear antibody (ANA), smooth muscle antibody (SMA), liver‑kidney microsomal type 1 antibody (LKM‑1) or soluble liver antigen/liver pancreas antigen (SLA/LP), how should autoimmune hepatitis be diagnosed and managed?

Diagnosis of Autoimmune Hepatitis in a Young Woman with Acute Hepatitis

In a woman aged 20-40 years presenting with fatigue, jaundice, right-upper-quadrant discomfort, transaminases >10× ULN, hypergammaglobulinemia, and positive autoantibodies (ANA, SMA, LKM-1, or SLA/LP), autoimmune hepatitis should be diagnosed using the simplified diagnostic scoring system and confirmed with liver biopsy showing interface hepatitis, followed by immediate initiation of corticosteroid-based immunosuppression.

Diagnostic Algorithm

Step 1: Exclude Competing Diagnoses First

Before diagnosing AIH, you must systematically rule out conditions that can mimic this presentation:

• Test for viral hepatitis: Check HBsAg, anti-HBc, anti-HCV with reflex HCV RNA, anti-HAV IgM, and anti-HEV IgG/IgM, as viral hepatitis can present with positive autoantibodies and must be excluded before starting immunosuppression 1, 2
• Obtain detailed drug history: Specifically ask about nitrofurantoin, minocycline, alpha-methyldopa, hydralazine, isoniazid, immune checkpoint inhibitors, and all herbal/over-the-counter supplements, as drug-induced liver injury accounts for approximately 9% of cases initially diagnosed as AIH 1, 2
• Consider acute EBV infection: Check EBV VCA IgM and EBNA IgG, as EBV can cause elevated transaminases, positive ANA, fatigue, and even false-positive HAV IgM—and typically resolves spontaneously without immunosuppression 2
• Exclude Wilson's disease: Check serum ceruloplasmin and 24-hour urinary copper in all patients under age 40, as this is a critical treatable diagnosis that worsens with corticosteroids 2
• Assess alcohol intake: Document consumption <25 g/day (adds +2 points to diagnostic score) versus >60 g/day (subtracts -2 points) 1

Step 2: Complete Autoantibody Panel and Biochemical Assessment

• Measure serum IgG or gamma-globulin levels: Approximately 85% of AIH patients have levels >1.5× ULN, which adds +2 to +3 points to the diagnostic score 1, 2
• Document autoantibody titers precisely: ANA or SMA ≥1:80 adds +2 points (≥1:40 adds +1 point); anti-LKM1 ≥1:40 or positive anti-SLA/LP adds +2 points 1
• Calculate ALP/AST ratio: A ratio <1.5 adds +2 points and strongly supports AIH; a ratio >3.0 subtracts -2 points and suggests a cholestatic process requiring evaluation for AIH-PBC or AIH-PSC overlap 1, 2
• If cholestatic pattern present: Perform anti-mitochondrial antibody (AMA) testing and MRCP or ERCP to evaluate for overlap syndromes 1

Step 3: Apply the Simplified Diagnostic Scoring System

The simplified system is preferred for clinical practice and requires the following 1:

Feature	Criteria	Points
Autoantibodies	ANA or SMA ≥1:40	+1
	ANA or SMA ≥1:80, or LKM-1 ≥1:40, or SLA positive	+2 (maximum)
IgG level	>ULN	+1
	>1.1× ULN	+2
Liver histology	Compatible with AIH	+1
	Typical for AIH	+2
Viral markers	Negative	+2

Interpretation: ≥6 points = probable AIH; ≥7 points = definite AIH 1

In your patient: Female sex (+2 points in revised system), ANA/SMA/LKM-1/SLA positive (+2), IgG elevated >1.5× ULN (+2), negative viral markers (+2) = already 8 points before biopsy, indicating definite AIH 1, 2

Step 4: Perform Liver Biopsy for Confirmation

Liver biopsy is mandatory before initiating immunosuppression unless acute liver failure requires immediate treatment 2:

• Interface hepatitis (lymphoplasmacytic infiltrate disrupting the limiting plate) is the histologic hallmark and adds +3 points in the revised scoring system 1, 2
• Plasma cell infiltration is characteristic (though not required) and adds +1 point 1
• Hepatocyte rosetting adds +1 point 1
• Assess fibrosis stage: The presence of cirrhosis or advanced fibrosis (stage 3-4) is an adverse prognostic factor that mandates treatment even with mild biochemical activity 1
• Exclude biliary changes: Absence of bile duct injury helps rule out overlap syndromes; biliary changes subtract -3 points 1

Critical Diagnostic Pitfalls to Avoid

• Do not dismiss AIH based on "atypical" autoantibody patterns: Approximately 20% of AIH patients are seronegative for standard autoantibodies, and 29-39% of acute severe AIH cases have absent or weakly positive ANA 2, 3
• Do not assume drug-induced liver injury resolves quickly: Patients may have been taking the causative drug for months to years before presentation, and the latency period for AIH-like DILI ranges from 1-8 weeks to 3-12 months 1
• Do not delay biopsy awaiting "more typical" features: In acute presentations, diagnostic scores are typically lower than in classical chronic presentations, but histology remains essential 3
• Do not overlook EBV in young adults: EBV can mimic AIH completely and resolves spontaneously; check EBV serology before committing to long-term immunosuppression 2

Management Strategy

Indications for Immediate Treatment

Your patient meets clear criteria for treatment based on the following 1:

• Moderate to severe inflammation: Transaminases >10× ULN with hypergammaglobulinemia indicates severe disease with clear survival benefit from immunosuppression 1
• Young age (20-40 years): Treatment is indicated to prevent cirrhosis development over several decades 1
• Female sex and symptomatic presentation: Fatigue, jaundice, and RUQ discomfort indicate active disease requiring intervention 1

First-Line Treatment Regimen

Standard induction therapy consists of prednisone 15-20 mg/day combined with azathioprine 1-2 mg/kg/day, supported by randomized controlled trial data showing improved 2-4 year survival 2:

• Check TPMT enzyme activity before starting azathioprine to identify patients at risk for severe myelosuppression 4
• Monitor liver enzymes every 2-4 weeks initially to establish treatment response 2
• Therapeutic goal: Complete normalization of both transaminases and IgG/globulins, as persistent inflammation increases risk of fibrotic progression 2

Alternative Regimens for Specific Scenarios

• If azathioprine intolerant or TPMT deficient: Use prednisone monotherapy at higher doses (40-60 mg/day initially) 4
• If cirrhosis with portal hypertension present: Consider budesonide 9 mg/day instead of prednisone to reduce systemic corticosteroid side effects, though data are limited 4
• If acute severe AIH with coagulopathy: Initiate high-dose prednisolone immediately while evaluating for liver transplantation 3

Monitoring and Long-Term Considerations

• Biochemical remission is defined as normalization of AST, ALT, and IgG, typically achieved within 6-12 months in 65-80% of patients 4
• Histologic remission lags behind biochemical remission by 3-6 months; consider repeat biopsy before attempting drug withdrawal 4
• Relapse occurs in 50-90% of patients after drug withdrawal, requiring long-term maintenance therapy in most cases 4
• If cirrhosis present at diagnosis: Initiate hepatocellular carcinoma surveillance with ultrasound every 6 months and screen for varices with upper endoscopy 1

Special Consideration: Overlap Syndromes

If your patient develops a cholestatic pattern (elevated ALP) during follow-up:

• Perform AMA testing: Positive AMA suggests AIH-PBC overlap 1
• Obtain MRCP or ERCP: Bile duct abnormalities suggest AIH-PSC overlap 1
• Overlap syndromes occur in 5-10% of AIH patients and may require combination therapy with ursodeoxycholic acid 1